Publication:
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

Simple item page
dc.contributor.authorFeng, Xiaojun
dc.contributor.authorSoldevila Verdeguer, Carla
dc.contributor.authorJafari, Samineh
dc.contributor.authorMemariani, Zahra
dc.contributor.authorTewari, Devesh
dc.contributor.authorAnnunziata, Giuseppe
dc.contributor.authorBarrea, Luigi
dc.contributor.authorHassan, Sherif T. S
dc.contributor.authorSmejkal, Karel
dc.contributor.authorMalanik, Milan
dc.contributor.authorSychrova, Alice
dc.contributor.authorBarreca, Davide
dc.contributor.authorZiberna, Lovro
dc.contributor.authorMahomoodally, Mohamad Fawzi
dc.contributor.authorZengin, Gokhan
dc.contributor.authorXu, Suowen
dc.contributor.authorNabavi, Seyed Mohammad
dc.contributor.authorShen, Ai-Zong
dc.date.accessioned2024-09-10T13:09:00Z
dc.date.available2024-09-10T13:09:00Z
dc.date.issued2019
dc.description.abstractCardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.en
dc.description.sponsorshipThe work was supported by National Nature Science Foundation of China (81603339, 81602344) and Natural Science Foundation of Anhui Province (1708085QH175). S. X. is a recipient of Career Development Award from American Heart Association (18CDA34110359). L. Z. was supported by Slovenian Research Agency ARRS (J3-8209). A. S. was supported by the Institute of Health Carlos III (Project CIBEROBN CB12/03/30038).es_ES
dc.format.number7es_ES
dc.format.page1923-1951es_ES
dc.format.volume9es_ES
dc.identifier.citationFeng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G, et al. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics. 2019;9(7):1923-51.en
dc.identifier.doi10.7150/thno.30787
dc.identifier.issn1838-7640
dc.identifier.journalTheranosticses_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/17155
dc.identifier.pubmedID31037148es_ES
dc.identifier.puiL627547235
dc.identifier.scopus2-s2.0-85065480668
dc.identifier.urihttps://hdl.handle.net/20.500.12105/22727
dc.identifier.wos461767700008
dc.language.isoengen
dc.publisherIvyspring International Publisher
dc.relation.publisherversionhttps://dx.doi.org/10.7150/thno.30787en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution-NonCommercial 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectBerberine
dc.subjectCardiovascular diseases
dc.subjectMetabolic diseases
dc.subjectTargets
dc.subjectTherapeutics
dc.subject.decsEnfermedades Metabólicas*
dc.subject.decsAnimales*
dc.subject.decsHumanos*
dc.subject.decsBerberina*
dc.subject.decsEnfermedades Cardiovasculares*
dc.subject.decsSistema Cardiovascular*
dc.subject.meshCardiovascular Diseases*
dc.subject.meshCardiovascular System*
dc.subject.meshBerberine*
dc.subject.meshAnimals*
dc.subject.meshHumans*
dc.subject.meshMetabolic Diseases*
dc.titleBerberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeuticsen
dc.typereview articleen
dspace.entity.typePublication
relation.isPublisherOfPublication0d14df1e-96a8-41a6-812c-2c5503661f38
relation.isPublisherOfPublication.latestForDiscovery0d14df1e-96a8-41a6-812c-2c5503661f38

Files

Collections

IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)